181 related articles for article (PubMed ID: 16002461)
1. Progress toward acetate supplementation therapy for Canavan disease: glyceryl triacetate administration increases acetate, but not N-acetylaspartate, levels in brain.
Mathew R; Arun P; Madhavarao CN; Moffett JR; Namboodiri MA
J Pharmacol Exp Ther; 2005 Oct; 315(1):297-303. PubMed ID: 16002461
[TBL] [Abstract][Full Text] [Related]
2. A safety trial of high dose glyceryl triacetate for Canavan disease.
Segel R; Anikster Y; Zevin S; Steinberg A; Gahl WA; Fisher D; Staretz-Chacham O; Zimran A; Altarescu G
Mol Genet Metab; 2011 Jul; 103(3):203-6. PubMed ID: 21474353
[TBL] [Abstract][Full Text] [Related]
3. Metabolic acetate therapy improves phenotype in the tremor rat model of Canavan disease.
Arun P; Madhavarao CN; Moffett JR; Hamilton K; Grunberg NE; Ariyannur PS; Gahl WA; Anikster Y; Mog S; Hallows WC; Denu JM; Namboodiri AM
J Inherit Metab Dis; 2010 Jun; 33(3):195-210. PubMed ID: 20464498
[TBL] [Abstract][Full Text] [Related]
4. Canavan disease and the role of N-acetylaspartate in myelin synthesis.
Namboodiri AM; Peethambaran A; Mathew R; Sambhu PA; Hershfield J; Moffett JR; Madhavarao CN
Mol Cell Endocrinol; 2006 Jun; 252(1-2):216-23. PubMed ID: 16647192
[TBL] [Abstract][Full Text] [Related]
5. Uncoupling N-acetylaspartate from brain pathology: implications for Canavan disease gene therapy.
von Jonquieres G; Spencer ZHT; Rowlands BD; Klugmann CB; Bongers A; Harasta AE; Parley KE; Cederholm J; Teahan O; Pickford R; Delerue F; Ittner LM; Fröhlich D; McLean CA; Don AS; Schneider M; Housley GD; Rae CD; Klugmann M
Acta Neuropathol; 2018 Jan; 135(1):95-113. PubMed ID: 29116375
[TBL] [Abstract][Full Text] [Related]
6. N-Acetylaspartate Synthase Deficiency Corrects the Myelin Phenotype in a Canavan Disease Mouse Model But Does Not Affect Survival Time.
Maier H; Wang-Eckhardt L; Hartmann D; Gieselmann V; Eckhardt M
J Neurosci; 2015 Oct; 35(43):14501-16. PubMed ID: 26511242
[TBL] [Abstract][Full Text] [Related]
7. Glyceryl triacetate for Canavan disease: a low-dose trial in infants and evaluation of a higher dose for toxicity in the tremor rat model.
Madhavarao CN; Arun P; Anikster Y; Mog SR; Staretz-Chacham O; Moffett JR; Grunberg NE; Gahl WA; Namboodiri AMA
J Inherit Metab Dis; 2009 Oct; 32(5):640. PubMed ID: 19685155
[TBL] [Abstract][Full Text] [Related]
8. Triacetin-based acetate supplementation as a chemotherapeutic adjuvant therapy in glioma.
Tsen AR; Long PM; Driscoll HE; Davies MT; Teasdale BA; Penar PL; Pendlebury WW; Spees JL; Lawler SE; Viapiano MS; Jaworski DM
Int J Cancer; 2014 Mar; 134(6):1300-10. PubMed ID: 23996800
[TBL] [Abstract][Full Text] [Related]
9. Defective N-acetylaspartate catabolism reduces brain acetate levels and myelin lipid synthesis in Canavan's disease.
Madhavarao CN; Arun P; Moffett JR; Szucs S; Surendran S; Matalon R; Garbern J; Hristova D; Johnson A; Jiang W; Namboodiri MA
Proc Natl Acad Sci U S A; 2005 Apr; 102(14):5221-6. PubMed ID: 15784740
[TBL] [Abstract][Full Text] [Related]
10. Acetate supplementation as a means of inducing glioblastoma stem-like cell growth arrest.
Long PM; Tighe SW; Driscoll HE; Fortner KA; Viapiano MS; Jaworski DM
J Cell Physiol; 2015 Aug; 230(8):1929-43. PubMed ID: 25573156
[TBL] [Abstract][Full Text] [Related]
11. N-acetylaspartate supports the energetic demands of developmental myelination via oligodendroglial aspartoacylase.
Francis JS; Wojtas I; Markov V; Gray SJ; McCown TJ; Samulski RJ; Bilaniuk LT; Wang DJ; De Vivo DC; Janson CG; Leone P
Neurobiol Dis; 2016 Dec; 96():323-334. PubMed ID: 27717881
[TBL] [Abstract][Full Text] [Related]
12. Suppressing N-Acetyl-l-Aspartate Synthesis Prevents Loss of Neurons in a Murine Model of Canavan Leukodystrophy.
Sohn J; Bannerman P; Guo F; Burns T; Miers L; Croteau C; Singhal NK; McDonough JA; Pleasure D
J Neurosci; 2017 Jan; 37(2):413-421. PubMed ID: 28077719
[TBL] [Abstract][Full Text] [Related]
13. Canavan disease, a rare early-onset human spongiform leukodystrophy: insights into its genesis and possible clinical interventions.
Baslow MH; Guilfoyle DN
Biochimie; 2013 Apr; 95(4):946-56. PubMed ID: 23151389
[TBL] [Abstract][Full Text] [Related]
14. Effects of ethanol and of alcohol dehydrogenase inhibitors on the reduction of N-acetylaspartate levels of brain in mice in vivo: a search for substances that may have therapeutic value in the treatment of Canavan disease.
Baslow MH; Suckow RF; Hungund BL
J Inherit Metab Dis; 2000 Nov; 23(7):684-92. PubMed ID: 11117430
[TBL] [Abstract][Full Text] [Related]
15. Canavan disease. Analysis of the nature of the metabolic lesions responsible for development of the observed clinical symptoms.
Baslow MH; Resnik TR
J Mol Neurosci; 1997 Oct; 9(2):109-25. PubMed ID: 9407392
[TBL] [Abstract][Full Text] [Related]
16. The effects of lithium chloride and other substances on levels of brain N-acetyl-L-aspartic acid in Canavan disease-like rats.
Baslow MH; Kitada K; Suckow RF; Hungund BL; Serikawa T
Neurochem Res; 2002 May; 27(5):403-6. PubMed ID: 12064356
[TBL] [Abstract][Full Text] [Related]
17. Aspartoacylase is restricted primarily to myelin synthesizing cells in the CNS: therapeutic implications for Canavan disease.
Kirmani BF; Jacobowitz DM; Kallarakal AT; Namboodiri MA
Brain Res Mol Brain Res; 2002 Nov; 107(2):176-82. PubMed ID: 12487123
[TBL] [Abstract][Full Text] [Related]
18. Canavan disease: clinical features and recent advances in research.
Hoshino H; Kubota M
Pediatr Int; 2014 Aug; 56(4):477-83. PubMed ID: 24977939
[TBL] [Abstract][Full Text] [Related]
19. Ablating N-acetylaspartate prevents leukodystrophy in a Canavan disease model.
Guo F; Bannerman P; Mills Ko E; Miers L; Xu J; Burns T; Li S; Freeman E; McDonough JA; Pleasure D
Ann Neurol; 2015 May; 77(5):884-8. PubMed ID: 25712859
[TBL] [Abstract][Full Text] [Related]
20. N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology.
Moffett JR; Ross B; Arun P; Madhavarao CN; Namboodiri AM
Prog Neurobiol; 2007 Feb; 81(2):89-131. PubMed ID: 17275978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]